Drug class
- Glycopyrrolate (oral)
- Quaternary-ammonium sweat-reducing medicine
- Oxybutynin
- Tertiary-amine sweat-reducing medicine and antispasmodic
·Comparison
Short answer
Both are off-label pills that reduce sweat across the body. Their common side effects are similar. Oxybutynin enters the brain more readily, so drowsiness, confusion, or memory problems may be more likely.
| Criterion | Glycopyrrolate (oral) | Oxybutynin |
|---|---|---|
| Drug class | Quaternary-ammonium sweat-reducing medicine | Tertiary-amine sweat-reducing medicine and antispasmodic |
| FDA approval | Peptic ulcer, antisialagogue (off-label for excessive sweating) | Overactive bladder (off-label for excessive sweating) |
| Typical adult dose | 1-8 mg daily, titrated | 2.5-10 mg daily, titrated |
| Formulations | Tablet (IR) | Tablet (IR), extended-release |
| how readily it enters the brain | Limited (quaternary structure) | Notable (tertiary structure) |
| Cognitive side-effect risk | Lower | Higher (especially in older adults) |
| Body area coverage | Whole-body, covers all sweat body areas | Whole-body, covers all sweat body areas |
Glycopyrrolate enters the brain less readily than oxybutynin. Oxybutynin may therefore cause more drowsiness, confusion, or memory problems. This matters most for older adults.
Both can cause dry mouth, blurred vision, constipation, trouble urinating, dry eyes, and too little sweating. Other medicines can add to these effects.
Neither drug has gone through a large late-stage trial for excessive sweating. Support comes from smaller studies, past medical records, and years of clinical use. Both uses are off-label.
·Read next
Treatments compared
Body areas
Study measures